TICKERNERD
Menu
FTHHealthcare · Biotechnology

FTH Stock Forecast: Faeth Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$32
+0.05% on the day

The 11 Wall Street analysts covering Faeth Therapeutics, Inc. hold a median 12-month price target of $55 — +71.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$826.9M
Ticker Nerd rank
54 / 100
Median analyst target
$55
Analysts covering
11
Total return, dividends reinvested
1W
−0.7%
1M
+13.2%
YTD
+201.0%
1Y
+325.6%
From 52W high
−11.2%
From 52W low
+325.6%
$8
$36
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FTH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Faeth Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
54 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
89
Momentum
85
Value
69
Revisions
61
Size
48
Quality
40
Issuance
34
Growth
19
Volatility
10

Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (10): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FTH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FTH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26FTHHigh $60Median $55Low $46

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $46Median $55High $60

The green dot is the last close — the median target sits +71.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Aug 2026NeedhamInitiatesBuy$56
11 Aug 2026HC Wainwright & Co.ReiteratesBuy$60
4 Aug 2026Jones TradingInitiatesBuy$55
31 July 2026Raymond JamesInitiatesOutperform$56
31 July 2026Raymond JamesInitiatesOutperform—
28 July 2026OppenheimerInitiatesOutperform$60
28 July 2026OppenheimerInitiatesOutperform—
20 July 2026CitizensInitiatesMarket Outperform$51
20 July 2026CitizensInitiatesMarket Outperform—
16 July 2026BTIGReiteratesBuy—
16 July 2026BTIGReiteratesBuy$55
26 June 2026BairdInitiatesOutperform$57
26 June 2026BairdInitiatesOutperform—
22 June 2026HC Wainwright & Co.InitiatesBuy$60
22 June 2026HC Wainwright & Co.InitiatesBuy—
15 June 2026BTIGReiteratesBuy—
11 June 2026BTIGInitiatesBuy—
29 May 2026Cantor FitzgeraldInitiatesOverweight—
28 May 2026LUCID CAPITAL MARKETSInitiatesBuy—
22 May 2026CitigroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FTH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

FTH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Faeth Therapeutics, Inc. (FTH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.9×

Cheaper than 85% of US stocks

Price / sales
—
Price / book
4.8×

Cheaper than 23% of US stocks

EV / EBITDA
−17.5×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−195.3%

Higher than 7% of US stocks

Return on assets
−20.8%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

FTH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FTHFaeth Therapeutics, Inc.$826.9M
54
ACHVAchieve Life Sciences, Inc.$820.2M
29
AURAAura Biosciences, Inc.$806.4M
41
RIGLRigel Pharmaceuticals, Inc.$849.1M
79
TBPHTheravance Biopharma, Inc.$856.6M
89
FDMT4D Molecular Therapeutics, Inc.$874.5M
53
SGPSpyGlass Pharma, Inc.$883.2M
1

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Faeth Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FTH news & analysis

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer

Business Wire · 17 Aug 2026positive

Faeth Therapeutics announced that the FDA has granted Fast Track designation to the combination of PIKTOR (sapanisertib and serabelisib) with paclitaxel for treating patients with advanced or recurrent endometrial cancer who have tumors with a PI3K/AKT/mTOR pathway alteration. The designation applies to the company's lead program PIKTOR.

Why it matters — Fast Track designation may expedite development and review of PIKTOR, a lead program central to Faeth's oncology pipeline, in a biomarker-selected advanced endometrial cancer setting.

Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments

Business Wire · 14 Aug 2026positive

Faeth Therapeutics announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice President, Investor Relations, as the company prepares for upcoming PIKTOR clinical milestones. Tiwari will oversee chemistry, manufacturing and controls (CMC), and supply chain activities supporting Faeth's PIKTOR clinical development program.

Why it matters — FTH watchers would care because these senior leadership additions signal the company's preparation to advance its PIKTOR clinical program toward upcoming milestones.

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 7 Aug 2026neutral

Faeth Therapeutics announced that its Compensation Committee granted two new employees options to purchase an aggregate of 11,000 shares of common stock, effective August 4, 2026, under the company's 2026 Inducement Plan as a material inducement to their employment.

Why it matters — FTH watchers would care because the equity grants reflect the company's use of inducement awards to attract and retain new employees, a routine corporate governance matter under Nasdaq Listing Rule 5635(c)(4).

Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference

Business Wire · 7 Aug 2026neutral

Faeth Therapeutics will present translational data and pharmacokinetic/pharmacodynamic (PK/PD) analysis for PIKTOR, its oral combination of serabelisib and sapanisertib, at the 2026 STOP Cancer conference held August 7-8 in New York. The presentation covers PK/PD modeling that informed PIKTOR dose selection in the ongoing FTH-PIK-201 trial.

Why it matters — FTH watchers would be interested as the presentation provides scientific disclosure on the translational data and PK/PD modeling underpinning PIKTOR's dose selection in its ongoing clinical trial.

Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates

Business Wire · 4 Aug 2026positive

Faeth Therapeutics announced its financial results for the quarter ended June 30, 2026 and highlighted recent corporate accomplishments and 2026 milestones for its investigational oncology candidate PIKTOR. CEO Anand Parikh described the company's combination with Sensei Biotherapeutics as an important milestone in Faeth's history.

Why it matters — A Faeth Therapeutics watcher would care because the report confirms the Sensei Biotherapeutics combination and details progress on PIKTOR and upcoming 2026 milestones for the clinical-stage company.

FAQ

Frequently asked questions about FTH stock

What is the FTH stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Faeth Therapeutics, Inc. have a median 12-month price target of $55, with estimates ranging from $46 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FTH stock a buy right now?

Of the 11 analysts covering Faeth Therapeutics, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Faeth Therapeutics, Inc. 54 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FTH?

As at 22 Aug 2026, Faeth Therapeutics, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).

Will FTH stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +71.3% from the last close, and Ticker Nerd's factor model ranks Faeth Therapeutics, Inc. 54 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FTH stock forecast for 2030?

No analyst covering Faeth Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FTH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $60 over the next 12 months.

How has FTH stock performed over the past year?

Faeth Therapeutics, Inc. returned +325.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Faeth Therapeutics, Inc. do?

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on integrating tumor metabolism into modern oncology treatment.

What is the latest news on FTH?

The most recent item we track (Business Wire, 17 Aug 2026): "Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer". Faeth Therapeutics announced that the FDA has granted Fast Track designation to the combination of PIKTOR (sapanisertib and serabelisib) with paclitaxel for treating patients with advanced or recurrent endometrial cancer who have tumors with a PI3K/AKT/mTOR pathway alteration. The designation applies to the company's lead program PIKTOR.

Company

About Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on integrating tumor metabolism into modern oncology treatment. The company develops multi-node therapies that target the PAM (PI3K/AKT/mTOR) signaling pathway, one of the most frequently altered oncogenic pathways in cancer, with the aim of blocking cancer growth signals while also managing the nutrient supply that fuels tumors. Its lead program, PIKTOR, is an all-oral investigational combination designed to achieve deeper pathway suppression with improved tolerability by inhibiting multiple nodes simultaneously. Faeth Therapeutics leverages a data-driven discovery platform that links tumor genotypes with specific therapeutic regimens and precision metabolic interventions, including nutrition-based strategies, to modulate cancer metabolism. Headquartered in San Francisco, California, and operating as a biotechnology research company, Faeth Therapeutics plays a specialized role in the oncology market by advancing metabolism-focused treatments for solid tumors within the broader biopharmaceutical and cancer therapeutics ecosystem.

CEO Mr. Anand Parikh Esq., J.D. · 29 employees · United States · https://www.faeththerapeutics.com